A first in human study of repeat dosing with REGN2810 a fully human antibody to programmed death - 1 (PD-1) as single therapy and in combination with selected
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
January 1, 2016
End Date
July 21, 2020
Administered By
Duke Cancer Institute
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
January 1, 2016
End Date
July 21, 2020